1-2 of 2
Stephen F. Hawkins, MBChB, MRCP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen
Journal: Blood
Blood (2018) 132 (Supplement 1): 306.
https://doi.org/10.1182/blood-2018-99-116624
Published: 2018
Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 835.
https://doi.org/10.1182/blood.V130.Suppl_1.835.835
Published: 2017